In the fight against cancer, it’s boom times for radiopharmaceuticals

When Ken Song was getting ready to leave his job as the CEO of a small biotech in 2020, he wasn’t sure what was next. But he knew one thing.

“I deliberately said I’m not going to do oncology. Oncology is so crowded. Everybody thinks they have the solution, but the reality is, it’s all noise,” he said.

That was until late March 2020, when he received two phone calls from two different investors, both pondering about the same thing: Was it possible to make more effective and widely applicable treatments that drop toxic radiation specifically to cancer cells, decimating them on site?

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In